Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors

Tamoxifen is the most commonly prescribed therapy for patients with estrogen receptor (ER)α-positive breast tumors. Tumor resistance to tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress human epidermal growth factor receptor 2 (HER2). Current precl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cittelly, Diana M., Das, Partha M., Salvo, Virgilio A., Fonseca, Juan P., Burow, Matthew E., Jones, Frank E.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2010
Matèries:
Cancer Biology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2994280/
https://ncbi.nlm.nih.gov/pubmed/20876285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/carcin/bgq192
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars